Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors.
Goswami R, Mukherjee S, Wohlfahrt G, Ghadiyaram C, Nagaraj J, Chandra BR, Sistla RK, Satyam LK, Samiulla DS, Moilanen A, Subramanya HS, Ramachandra M. Goswami R, et al. Among authors: wohlfahrt g. ACS Med Chem Lett. 2013 Oct 7;4(12):1152-7. doi: 10.1021/ml400213v. eCollection 2013 Dec 12. ACS Med Chem Lett. 2013. PMID: 24900621 Free PMC article.
Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.
Goswami R, Mukherjee S, Ghadiyaram C, Wohlfahrt G, Sistla RK, Nagaraj J, Satyam LK, Subbarao K, Palakurthy RK, Gopinath S, Krishnamurthy NR, Ikonen T, Moilanen A, Subramanya HS, Kallio P, Ramachandra M. Goswami R, et al. Among authors: wohlfahrt g. Bioorg Med Chem. 2014 Jun 15;22(12):3187-203. doi: 10.1016/j.bmc.2014.04.013. Epub 2014 Apr 18. Bioorg Med Chem. 2014. PMID: 24794746
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Goswami R, Wohlfahrt G, Törmäkangas O, Moilanen A, Lakshminarasimhan A, Nagaraj J, Arumugam KN, Mukherjee S, Chacko AR, Krishnamurthy NR, Jaleel M, Palakurthy RK, Samiulla DS, Ramachandra M. Goswami R, et al. Among authors: wohlfahrt g. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5309-14. doi: 10.1016/j.bmcl.2015.09.042. Epub 2015 Sep 21. Bioorg Med Chem Lett. 2015. PMID: 26421993
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.
Holmström TH, Moilanen AM, Ikonen T, Björkman ML, Linnanen T, Wohlfahrt G, Karlsson S, Oksala R, Korjamo T, Samajdar S, Rajagopalan S, Chelur S, Narayanan K, Ramachandra RK, Mani J, Nair R, Gowda N, Anthony T, Dhodheri S, Mukherjee S, Ujjinamatada RK, Srinivas N, Ramachandra M, Kallio PJ. Holmström TH, et al. Among authors: wohlfahrt g. Mol Cancer Ther. 2019 Jan;18(1):28-38. doi: 10.1158/1535-7163.MCT-18-0204. Epub 2018 Oct 9. Mol Cancer Ther. 2019. PMID: 30301864
Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
Oksala R, Moilanen A, Riikonen R, Rummakko P, Karjalainen A, Passiniemi M, Wohlfahrt G, Taavitsainen P, Malmström C, Ramela M, Metsänkylä HM, Huhtaniemi R, Kallio PJ, Mustonen MV. Oksala R, et al. Among authors: wohlfahrt g. J Steroid Biochem Mol Biol. 2019 Sep;192:105115. doi: 10.1016/j.jsbmb.2018.02.004. Epub 2018 Feb 10. J Steroid Biochem Mol Biol. 2019. PMID: 29438723 Free article.
Faulty epithelial polarity genes and cancer.
Tervonen TA, Partanen JI, Saarikoski ST, Myllynen M, Marques E, Paasonen K, Moilanen A, Wohlfahrt G, Kovanen PE, Klefstrom J. Tervonen TA, et al. Among authors: wohlfahrt g. Adv Cancer Res. 2011;111:97-161. doi: 10.1016/B978-0-12-385524-4.00003-9. Adv Cancer Res. 2011. PMID: 21704831 Review.
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis.
Karimaa M, Riikonen R, Kettunen H, Taavitsainen P, Ramela M, Chrusciel M, Karlsson S, Rummakko P, Simola O, Wohlfahrt G, Hakulinen P, Vuorela A, Joensuu H, Utriainen T, Fizazi K, Oksala R. Karimaa M, et al. Among authors: wohlfahrt g. Mol Cancer Ther. 2022 Dec 2;21(12):1765-1776. doi: 10.1158/1535-7163.MCT-22-0115. Mol Cancer Ther. 2022. PMID: 36129801
123 results